Hyungseok Kang
Masan, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and/or delamanid under the South Korean nationwide approval process.
Journal: BMC infectious diseases
Published: January 18, 2026
A comparison of phenotypic and WGS drug susceptibility testing in Mycobacterium tuberculosis isolates from the Republic of Korea.
Journal: JAC-antimicrobial resistance
Published: September 27, 2022
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease.
Journal: The European respiratory journal
Published: April 19, 2022
Clinical Features of Adult COVID-19 Patients without Risk Factors before and after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak in Korea: Experience from Gyeongsangnam-do.
Journal: Journal of Korean medical science
Published: October 12, 2021
Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 01, 2021
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
Journal: The European respiratory journal
Published: August 05, 2020
Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: June 08, 2020
Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation.
Journal: Journal of Korean medical science
Published: May 30, 2020
Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea.
Journal: Respiratory medicine
Published: November 26, 2019
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
Journal: The European respiratory journal
Published: April 23, 2019
Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
Journal: The Journal of antimicrobial chemotherapy
Published: June 10, 2017
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.
Journal: Lancet (London, England)
Published: September 04, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026